BOSTON, Oct. 19 /PRNewswire-FirstCall/ -- NMT Medical, Inc. announced that it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (the “SEC”). If and when the shelf registration statement is declared effective, it will permit the Company from time to time, to offer and sell up to $65 million of equity or debt securities. The offering of securities covered by the shelf registration statement is designed to provide the Company with greater flexibility to take advantage of financing opportunities, subject to market conditions and the capital requirements of the Company. As of the date of this release, the Company has no specific plans to offer the securities covered by the registration statement, and is not required to offer the securities in the future.
The terms of any offering under the registration statement will be established at the time of the offering and will be described in a prospectus supplement filed with the SEC at the time of the offering. Unless otherwise indicated in a prospectus supplement, the proceeds from the sale of any securities will be used for general corporate purposes including, but not limited to, sales and marketing expansion, working capital, capital expenditures, continuing research and development, acquisitions and investments.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release is not an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About NMT Medical, Inc.
NMT Medical is an advanced medical technology company that designs, develops, manufactures and markets proprietary implant technologies that allow interventional cardiologists to treat structural heart disease through minimally invasive, catheter-based procedures. NMT Medical is currently investigating the potential connection between a common cardiac defect called a PFO and brain attacks such as migraine headaches, stroke and transient ischemic attacks (TIAs). A PFO can allow venous blood, unfiltered and unmanaged by the lungs, to enter the arterial circulation of the brain, possibly triggering a cerebral event or brain attack. More than 21,000 PFOs have been treated globally with NMT’s minimally invasive, catheter-based implant technology. The prevalence of migraines in the United States is about 10%. Of the 28 million migraine sufferers in America, those who experience aura and have a PFO may represent a three million patient subset. Stroke is the third leading cause of death in the United States and the leading cause of disability in adults. Each year, 750,000 Americans suffer a new or recurrent stroke and an additional 500,000 Americans experience a TIA.
For more information about NMT Medical, please visit http://www.nmtmedical.com.
Contact: Richard E. Davis Vice President & Chief Financial Officer NMT Medical, Inc. (617) 737-0930 red@nmtmedical.com
NMT Medical, Inc.
CONTACT: Richard E. Davis, Vice President & Chief Financial Officer of NMTMedical, Inc., +1-617-737-0930, red@nmtmedical.com
